IE900233L - Low dose benazepril/thiazide diuretic composition - Google Patents
Low dose benazepril/thiazide diuretic compositionInfo
- Publication number
- IE900233L IE900233L IE900233A IE23390A IE900233L IE 900233 L IE900233 L IE 900233L IE 900233 A IE900233 A IE 900233A IE 23390 A IE23390 A IE 23390A IE 900233 L IE900233 L IE 900233L
- Authority
- IE
- Ireland
- Prior art keywords
- benazepril
- composition according
- hydrochlorothiazide
- thiazide diuretic
- dose
- Prior art date
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/55—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/12—Antihypertensives
Abstract
A fixed ratio low dose combination of benazepril and a thiazide diuretic is disclosed for treating hypertension. Particularly preferred is a composition having about 46 mg of benazepril hydrochloride and about 5-7.5 mg of hydrochlorothiazide per dosage form.
[CA2008126C]
Description
The invention relates to a pharmaceutical composition for treating mild to moderate hypertension containing the angiotensin converting enzyme inhibitor benazepril in combination with thiazide diuretics, and to a method of treatment of hypextension utilizing this composition.
Benazepril hydrochloride is a new orally active, non-sulfnydril containing, angiotensin The compound is described in U.S. 4,410,520. Thiazide diuretics, the second component of the instant combination, have long been a mainstay of antihypertensive therapy. All of the active agents of the instant invention are well known compounds in the art; their synthesis, routes of administration, etc. are well known. Additionally, there has been some literature published in recent years on combining angiotensin convening enzyme inhibitors with thiazide diuretics. See for example US 4,472,380, especially columns 9 and 10 and example 127 thereof; US 4,217,347, especially columns 2-3 and the examples; American J. Hypert. 1(1), 38-41 (1988); Patent Specification No„ 2392/86; J. Hypertension 1 (Suppl. 2), 384-386 (1983); and Amer. J. Hypert. 1 (3, pan 2), 13A-14A, Abstract 1226 (1988). However, each of these deal with angiotensin converting enzyme inhibiting drugs other than benazepril and/or diuretics in amounts substantially greater than that in the present invention. Probably the most significant reference is Merck's South African Patent Application 83 3903, claiming priority of US Application 383,435.
This reference discloses angiotensin converting enzyme inhibitors of benazepril type in amounts of 2.5-100 mg/day in combination with diuretics genetically in the range of 0.5-100 mg/day. Hydrochlorothiazide is only mentioned in amounts of at least 10 mg/day.
It is an object of the present invention to provide a pharmaceutical composition to treat saild co a o d e r aea hypertension with a minimum amount of active agent while achieving pressure reductions not achievable with the individual active agents at the same dosage.
The invention is a fixed ratio low dose combination of 4-6 mg benazepril or a pharmaceu-ticaliy acceptable salt thereof with 80-120 % of Vg of the initial daily antihypertensive clinically recommended dose of a thiazide diuretic given as a once daily dosage. The inventive composition is a daily unit dose for administration to a human adult having mild to moderate hypertension comprising 4 to 6 mg, preferably about 5 mg, benazepril hydrochloride or any other pharmaceutical^ acceptable salt of benazepril and 80 % to 120 %, preferably about 100 %, of Vs the usual initial antihypertensive adult clinical dose of a thiazide diuretic, when such diuretic is used alone.
Pharmaceutically acceptable salts of benazepril are acid addition salts with pharmacologically harmless acids, e.g. with inorganic acid, for example hydrochloric acid, sulfuric acid or phosphoric acid, or with organic carbonic, sulfonic or sulfo acids, for example acetic, propionic, glycolic, maleic, fumaric, tartaric, citric, benzoic, methanesulfonic, ethanesulfonic, or 2-hydroxyethanesulfonic acid. Preferred is the hydrochloride, i.e. the acid addition salt with hydrochloric acid.
Preferably the diuretic is selected from bendroflumethiazide (5 mg) 0.5 - 0.75 mg; chlorthalidone (25 mg) 2.5 - 3.75 mg; chlorothiazide (500 mg) 50 - 75 mg; hydrochlorothiazide (50 mg) 5 - 7.5 mg; hydroflumethiazide (50 mg) 5 - 7.5 mg; methylchlorothiazide (2.5 mg) 0.25 - 0.3S mg; polythiazide (2 mg) 0.2 - 0.3 mg; mchlormethiazide (2 mg) 0.2 - 0.3 mg; benzthiazide (50 mg) 0.5 - 0.75 mg; cyclothiazide (2 mg) 0.2 - 0.3 mg.
The usual minimum initial clinical antihypertensive adult dose is shown in parenthesis, followed by the dosage range useful in this invention. The initial clinical dose applied -3- nowadays may differ from the dose given in parenthesis in the list above for some cases. For example hydrochlorothiazide is often given in an initial dose of 25 mg.
Mors preferably, me thiazide diuretic is selected from chlorothiazide, hydrochlorothiazide, mcthylchlorothiazide, and chlorthalidone. Most preferably, the thiazide diuretic Is selected 5 from chlorothiazide and hydrochlorothiazide; it is in parti.cw.lar hydrochlorothiazide.
The most advantageous composition comprises benazepril hydrochloride and hydrochlorothiazide in a weight ratio of about 0.8 to L for example about 5 mg benazepril hydrochloride and about 6.25 rng hydrochlorothiazide.
In © clinical double-blind randomized trial with 334 men and women having a sitting 1 o diastolic blood pressure of 95-114 mmHg, the efficacy of the preferred combination of the invention comprising 5 mg benazepril hydrochloride and 6.25 mg. hydrochlorothiazide given once daily was compared with the efficacy of other compositions and of the single drugs during six weeks. The results are summarized in the following table: 5 mg benazepril^ + 625 mg hydrochlorothiazide 15 10 rng benazepril 12.5 mg hydrochlorothiazide 20 mg benazepril + 25 mg hydrochlorothiazide 20 mg benazepril 25 mg hydrochlorothiazide 20 mg benazepril + 6.25 mg hydrochlorothiazide 20 5 mg benazepril + 25 mg hydrochlorothiazide placebo a) as the hydrochloride b) reduction of sitting diastolic blood pressure The clinical results demonstrate that the low dose composition of the invention has a > 5 surprising efficacy.
The composition can be put together by methods which are standard in the an in any convenient dosage form, including tablet, capsule, powder, etc. Any suitable pharmaceutical adjuvant or carrier may also be included. Administration may be by any route by which both benazepril and the thiazide diuretic may be simultaneously administered, but is most - 9.9 mmHgb) - 9.6 mmHg -13.9 mmHg - 9.8 mmHg - 6.9 mmHg -10.3 mmHg -10.7 mmHg - 3.9 mmHg preferably oral. The most suitable dosage form is a solid oral dosage form such as a tablet or capsule. While other antihypertensive active agents may be added, most preferably only benazepril and only one thiazide diuretic are present in any one composition.
Tile instant invention will be more fully understood by reference to the following example. which illustrates, but docs sot limit the invention.
H^awaole: Film-coated tablets, containing 6.25 mg 6-chlaro-3,4-dihydit>-2H-l ^2,4-ben2o-thiadiazinc-7-sulfonamide- 1,1-dioxide and 5.00 mg l
Claims (12)
1. -5 - clabmS.— 'y i. A Low dose pharmaceutical composition for sreating mild to moderate hypertension * comprising 4 to 6 mg of benazepril or a pharmaceutical^ acceptable salt of benazepril and a thiazide diuretic in an amount of 80 % to 120 % of i of she minimum. recornraended initial single adult dally antihypertensive dose of said thiazide diuretic when used alone, each amount being per unit dose of said composition.
2. A composition according to claim 1 wherein said thiazide diuretic is selected from bendroflumethiazide, chlorthalidone, chlorothiazide, hydrochlorothiazide, hydroflumethiazide, methylchlorothiazide, polvthlazide, crichlorrnethiazidc, benzthiazide, and cyclothiazide.
3. A composition according to claim 2 wherein said thiazide diuretic is hydrochlorothiazide.
4. A composition according to any of claims 1 to 3 wherein said thiazide diuretic is present in an amount which is } of the minimum recommended initial antihypertensive dose when the thiazide diuretic is used alone.
5. A composition according to claim 3 wherein said hydrochlorothiazide is present in an amount of 5 mg to 7.5 mg per dose.
6. A composition according to claim 5 wherein said hydrochlorothiazide is present in an amount of about 6.25 mg per dose.
7. A composition according to any of claims 1 to 6 wherein said benazepril or pharmaceutical^ acceptable salt thereof is benazepril hydrochloride.
8. A composition according to claim 7 wherein said benazepril hydrochloride is present in an amount of about 5 mg per dose. 25
9. A composition according to claim 1 comprising 5 mg benazepril hydrochloride and 6.25 mg hydrochlorothiazide per dose.
10. A composition according to any of claims 1 to 9 which is a tablet, a powder, or a capsule.
11. A composition according to claim 10 which is an oral tablet or oral capsule.
12. A composition according to claini 1 substantially as herein described with reference the example. F. R. KELLY & CO., AGENTS FOR THE APPLICANTS.
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US30038389A | 1989-01-23 | 1989-01-23 |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| IE900233L true IE900233L (en) | 1990-07-23 |
| IE61784B1 IE61784B1 (en) | 1994-11-30 |
Family
ID=23158879
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| IE23390A IE61784B1 (en) | 1989-01-23 | 1990-01-22 | Low dose benazepril/thiazide diuretic composition |
Country Status (24)
| Country | Link |
|---|---|
| JP (1) | JP3009694B2 (en) |
| KR (1) | KR0141479B1 (en) |
| AT (1) | AT401728B (en) |
| AU (1) | AU629288B2 (en) |
| BE (1) | BE1002736A4 (en) |
| CA (1) | CA2008126C (en) |
| CH (1) | CH680568A5 (en) |
| CY (1) | CY1835A (en) |
| DE (2) | DE4001496C2 (en) |
| DK (1) | DK175204B1 (en) |
| FR (1) | FR2641971B1 (en) |
| GB (1) | GB2227172B (en) |
| HK (1) | HK98995A (en) |
| IE (1) | IE61784B1 (en) |
| IL (1) | IL93117A0 (en) |
| IT (1) | IT1239744B (en) |
| LU (1) | LU87660A1 (en) |
| MX (1) | MX9203362A (en) |
| NL (1) | NL194958C (en) |
| NZ (1) | NZ232182A (en) |
| SA (1) | SA90100151B1 (en) |
| SE (1) | SE506179C2 (en) |
| SG (1) | SG176194G (en) |
| ZA (1) | ZA90429B (en) |
Families Citing this family (4)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| KR100221695B1 (en) * | 1991-08-12 | 1999-09-15 | 그린 마틴, 브라이언 쥐 테슬리 | Pharmaceutical spheroid formulation |
| DK9200258U4 (en) * | 1992-03-11 | 1993-07-23 | Merck & Co Inc | Pharmaceutical preparation containing enalapril for use in hypertension |
| GB9613470D0 (en) * | 1996-06-27 | 1996-08-28 | Ciba Geigy Ag | Small solid oral dosage form |
| CN102579346B (en) * | 2012-03-02 | 2013-09-25 | 海南美兰史克制药有限公司 | Liposome solid preparation of benazepril/hydrochlorothiazide medicine combination |
Family Cites Families (5)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US4217347A (en) * | 1977-12-27 | 1980-08-12 | E. R. Squibb & Sons, Inc. | Method of treating hypertension and medicaments therefor |
| IL58849A (en) * | 1978-12-11 | 1983-03-31 | Merck & Co Inc | Carboxyalkyl dipeptides and derivatives thereof,their preparation and pharmaceutical compositions containing them |
| US4410520A (en) * | 1981-11-09 | 1983-10-18 | Ciba-Geigy Corporation | 3-Amino-[1]-benzazepin-2-one-1-alkanoic acids |
| ZA833903B (en) * | 1982-06-01 | 1984-11-28 | Merck & Co Inc | Benzofused lactams as antihypertensives |
| US4520021A (en) * | 1982-07-02 | 1985-05-28 | Merck & Co., Inc. | Substituted caprolactam derivatives as antihypertensives |
-
1990
- 1990-01-08 SE SE9000050A patent/SE506179C2/en not_active IP Right Cessation
- 1990-01-15 CH CH112/90A patent/CH680568A5/de not_active IP Right Cessation
- 1990-01-17 GB GB9001054A patent/GB2227172B/en not_active Expired - Lifetime
- 1990-01-18 LU LU87660A patent/LU87660A1/en unknown
- 1990-01-19 NZ NZ232182A patent/NZ232182A/en unknown
- 1990-01-19 DE DE4001496A patent/DE4001496C2/en not_active Expired - Lifetime
- 1990-01-19 DE DE2001199041 patent/DE10199041I1/en active Pending
- 1990-01-19 CA CA002008126A patent/CA2008126C/en not_active Expired - Lifetime
- 1990-01-19 IT IT47548A patent/IT1239744B/en active IP Right Grant
- 1990-01-19 FR FR909000612A patent/FR2641971B1/en not_active Expired - Lifetime
- 1990-01-22 IL IL93117A patent/IL93117A0/en not_active IP Right Cessation
- 1990-01-22 NL NL9000158A patent/NL194958C/en not_active IP Right Cessation
- 1990-01-22 ZA ZA90429A patent/ZA90429B/en unknown
- 1990-01-22 AU AU48703/90A patent/AU629288B2/en not_active Expired
- 1990-01-22 IE IE23390A patent/IE61784B1/en not_active IP Right Cessation
- 1990-01-22 DK DK199000174A patent/DK175204B1/en not_active IP Right Cessation
- 1990-01-22 AT AT0013590A patent/AT401728B/en not_active IP Right Cessation
- 1990-01-22 JP JP2010782A patent/JP3009694B2/en not_active Expired - Lifetime
- 1990-01-22 BE BE9000074A patent/BE1002736A4/en not_active IP Right Cessation
- 1990-01-22 KR KR1019900000697A patent/KR0141479B1/en not_active IP Right Cessation
- 1990-04-04 SA SA90100151A patent/SA90100151B1/en unknown
-
1992
- 1992-06-25 MX MX9203362A patent/MX9203362A/en unknown
-
1994
- 1994-12-16 SG SG176194A patent/SG176194G/en unknown
-
1995
- 1995-06-22 HK HK98995A patent/HK98995A/en not_active IP Right Cessation
- 1995-12-01 CY CY183595A patent/CY1835A/en unknown
Also Published As
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| EP1437131B1 (en) | Use of ramipril for the prevention of diabetes in a patient with no preexisting congestive heart failure | |
| ZA9711606B (en) | Cyclosporin derivatives, their preparation and the pharmaceutical compositions which contain them. | |
| US6610682B2 (en) | Pharmaceutical compositions and methods for the treatment of arteriosclerosis | |
| BG105173A (en) | Novel salt form of pantoprazole | |
| HU194053B (en) | Process for preparing pharmaceutical compositions containing a combination of dihidro-pyridines and ace-inhibitors | |
| EP0244083A3 (en) | Amino acid derivatives | |
| JPH05255084A (en) | Agent for suppressing restenosis after percutaneous transluminal coronary angioplasty | |
| EP0220107A2 (en) | Use of angiotensin-converting enzyme inhibitors in macular degeneration | |
| EP0991424B1 (en) | Pharmaceutical compositions comprising an aldose reductase inhibitor and an ace inhibitor | |
| US4579846A (en) | Antiinflammatory compositions and methods | |
| IE900233L (en) | Low dose benazepril/thiazide diuretic composition | |
| US20020183291A1 (en) | Product for treating gynecomastia | |
| HU205714B (en) | Process for producing hypotensive pharmaceutical compositions by using combination of angiotensin converting enzyme inhibitors and potassium canal modulator | |
| CA2044511A1 (en) | Pharmaceutical resorption-improved somatostatin compositions, their preparation and use | |
| JP3598116B2 (en) | Pharmaceutical composition for the treatment of tardive dyskinesia and its use | |
| US4874757A (en) | Antinflammatory compositions and methods | |
| WO2023149700A1 (en) | Pharmaceutical composition comprising allopurinol, febuxostat or pharmaceutically acceptable salt thereof for prevention or treatment of chronic kidney disease in subject having high blood uric acid concentration | |
| JP3091518B2 (en) | Osteoporosis prevention and treatment agent | |
| HU200685B (en) | Process for producing combination pharmaceutical composition suitable for treating hypertension | |
| WO2023075461A1 (en) | Composite composition containing angiotensin receptor blocker and sglt2 inhibitor | |
| US4812455A (en) | Antiinflammatory compositions and methods | |
| HU228302B1 (en) | Use of levosimendan for the treatment or prevention of coronary graft vasospasm | |
| HU211747A9 (en) | Drugs containing verapamil and trandolapril | |
| KR960011773B1 (en) | Pharmaceutical compositions for the gastric ulcer prevention and therapy | |
| IE43955B1 (en) | Pharmaceutical composition and dosage units thereof |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| MK9A | Patent expired |